Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress (GlobeNewswire) - Oct 19, 2022 - P1/2a | N=18 | ReSPECT (NCT01906385) | Sponsor: Plus Therapeutics "There is a statistically significant overall survival benefit observed with 186RNL radiation doses over 100 Gray. In 23 adult patients across eight cohorts of increasing dose and treated over a seven-year period, the improved median overall survival (OS) rates correlated with the absorbed tumor radiation dose. Patients receiving a therapeutic absorbed radiation dose (>100 Gray) had a median OS of 129.7 weeks (95% CI of 35.0-169.1) compared to those receiving a subtherapeutic absorbed radiation dose (<100 Gray) whose median OS was 22.3 weeks (95% CI of 6.4-45.3). The Company plans to initiate a National Institutes of Health (NIH)-funded Phase 2 study by the end of 2022 that will utilize cGMP 186RNL and leverage a higher dose and volume that could potentially show a greater survival rate in patients with recurrent GBM."
P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|